Angle PLC Issue of Equity (1993K)
September 19 2016 - 6:14AM
UK Regulatory
TIDMAGL
RNS Number : 1993K
Angle PLC
19 September 2016
For immediate release 19 September 2016
ANGLE plc
("ANGLE" or "the Company")
Issue of Equity
ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech
company, announces that it has received notice from an employee to
exercise options over 22,000 ordinary shares of 10p each in the
Company. Share options were issued to employees pursuant to the
arrangements set out in the Company's Share Option Schemes.
Accordingly the Company has issued and allotted 22,000 new
ordinary shares of 10p each ("New Ordinary Shares") in the capital
of the Company. The New Ordinary Shares rank pari passu with the
existing ordinary shares in the Company. An application has been
made for the New Ordinary Shares to be admitted to trading on AIM
and admission is expected to take place at 8.00 am on 23 September
2016. Following this allotment, the total issued share capital of
the Company is 74,815,774 ordinary shares.
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser)
Russell Kerr, Olly Baxendale
(Sales) 020 7397 8900
WG Partners
David Wilson
Claes Spång 020 3705 9330
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China and
Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOELLFLIAVIALIR
(END) Dow Jones Newswires
September 19, 2016 06:14 ET (10:14 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024
